Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 288 Magnetic Resonance Spectroscopy 238 pembrolizumab 228 Carboplatin 187 Cisplatin 153 Biopsy 151 Cyclophosphamide 144 Paclitaxel 133 Nivolumab 123 Gemcitabine 113 Bevacizumab 106 Radiotherapy 96 Dexamethasone 86 Pemetrexed 83 fludarabine 78 Fluorouracil 76 Doxorubicin 76 Docetaxel 76 atezolizumab 73 Radiation 72 Leucovorin 70 Rituximab 68 Oxaliplatin 66 venetoclax 61 durvalumab 61 Prednisone 61 Vincristine 56 Cetuximab 56 Lenalidomide 55 Etoposide 54

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

efgartigimod alfa × 30 days × Clear all

NCT07217587 2026-06-05

EPIC

Janssen Research & Development, LLC

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡